Prostate Specific Antigen After Radiotherapy for Prostate Cancer: A Reevaluation of Long-Term Biochemical Control and Kinetics of Recurrence in Patients Treated at Stanford University
- 1 October 1995
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 154 (4) , 1412-1417
- https://doi.org/10.1016/s0022-5347(01)66879-4
Abstract
We evaluated prostate specific antigen (PSA) evidence for control of prostatic cancer after irradiation. We studied 110 patients for whom more than 2 PSA measurements were obtained to establish trends and the initial measurement was done between April 1985 and January 1988. A total of 42 patients (38%) had stable, normal PSA levels with followup averaging 12.4 years (range 4.4 to 24.8). Increasing clinical stage or Gleason score correlated significantly with risk for PSA relapse, as did pretreatment PSA level. Short PSA doubling times were associated with distant metastasis rather than with local recurrence. We found that irradiation durably controlled 38% of prostatic cancers of various stages and grades and is unlikely to accelerate tumor growth.Keywords
This publication has 17 references indexed in Scilit:
- Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancerCancer, 1994
- Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastasesUrology, 1994
- Radical Radiation Therapy in the Management of Prostatic Adenocarcinoma: The Initial Prostate Specific Antigen Value as a Predictor of Treatment OutcomeJournal of Urology, 1994
- Prostate-specific antigen kinetics after external beam irradiation for carcinoma of the prostateInternational Journal of Radiation Oncology*Biology*Physics, 1994
- Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancerCancer, 1993
- Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screeningPublished by American Medical Association (AMA) ,1993
- Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostateUrology, 1993
- The Use of Prostate Specific Antigen, Clinical Stage and Gleason Score to Predict Pathological Stage in Men with Localized Prostate CancerJournal of Urology, 1993
- Prostate Specific Antigen after Irradiation for Prostatic CarcinomaJournal of Urology, 1990
- Prostate Specific Antigen in the Diagnosis and Treatment of Adenocarcinoma of the Prostate. II. Radical Prostatectomy Treated PatientsJournal of Urology, 1989